Alps Advisors Inc. grew its stake in shares of Epizyme Inc (NASDAQ:EPZM) by 22.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 122,992 shares of the biopharmaceutical company’s stock after acquiring an additional 22,150 shares during the period. Alps Advisors Inc. owned 0.16% of Epizyme worth $1,304,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. bought a new stake in shares of Epizyme during the first quarter worth $187,000. BB&T Securities LLC lifted its holdings in shares of Epizyme by 45.5% during the second quarter. BB&T Securities LLC now owns 16,000 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 5,000 shares during the period. Jane Street Group LLC acquired a new position in shares of Epizyme during the first quarter worth $273,000. BlueMountain Capital Management LLC acquired a new position in shares of Epizyme during the second quarter worth $320,000. Finally, Trexquant Investment LP acquired a new position in shares of Epizyme during the second quarter worth $328,000. 71.03% of the stock is currently owned by institutional investors.
Several research firms recently issued reports on EPZM. Cowen reiterated a “buy” rating on shares of Epizyme in a report on Monday, September 24th. Cann reiterated a “buy” rating and set a $27.00 price objective on shares of Epizyme in a report on Thursday, August 2nd. BidaskClub upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a report on Thursday, August 16th. ValuEngine raised shares of Epizyme from a “sell” rating to a “hold” rating in a research report on Thursday, July 26th. Finally, Morgan Stanley set a $12.00 target price on shares of Epizyme and gave the stock a “hold” rating in a research report on Friday, September 7th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. Epizyme presently has an average rating of “Hold” and an average price target of $20.50.
In other news, Director David M. Mott bought 416,667 shares of the stock in a transaction on Friday, October 5th. The shares were acquired at an average cost of $9.00 per share, for a total transaction of $3,750,003.00. Following the purchase, the director now directly owns 12,088 shares of the company’s stock, valued at approximately $108,792. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 21.50% of the company’s stock.
Shares of EPZM stock traded down $0.23 during trading on Thursday, reaching $7.00. 585,341 shares of the company’s stock traded hands, compared to its average volume of 578,950. The stock has a market capitalization of $572.39 million, a P/E ratio of -3.21 and a beta of 1.89. Epizyme Inc has a 1 year low of $6.90 and a 1 year high of $21.40.
Epizyme (NASDAQ:EPZM) last posted its earnings results on Friday, November 2nd. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.07. On average, sell-side analysts anticipate that Epizyme Inc will post -1.93 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://theenterpriseleader.com/2018/11/22/epizyme-inc-epzm-stake-lifted-by-alps-advisors-inc.html.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Featured Article: How to read a candlestick chart
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.